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Abstract
Context. -: Myeloid sarcoma (MS) is a neoplasm of immature granulocytes, monocytes, or both
involving any extramedullary site. The correct diagnosis of MS is important for adequate therapy,
which is often delayed because of a high misdiagnosis rate.
Objective. -: To evaluate the lineage differentiation of neoplastic cells in MS by
immunohistochemistry, and to correlate the results with clinicopathologic findings and cytogenetic
studies.
Design. -: Histologic and immunohistochemical examinations were performed on formalin-fixed
paraffin-embedded tissue samples from 13 cases of MS. They were classified according to the
World Health Organization criteria. Chromosomal analysis data were available in 11 cases. Clinical,
pathological, and cytogenetic findings were analyzed.
Results. -: The study included six male and seven female patients with an age range of 25 to 72
years (mean, 49.3 years) and a male to female ratio of 1:1.2. MS de novo occurred in 4/13 (31%) of
cases examined. The most sensitive immunohistochemical markers were CD43 and lysozyme
present in all cases with MS (13/13, 100%). All de novo MS showed a normal karyotype,
monoblastic differentiation, and lack of CD34. The most common chromosomal abnormalities in
MS associated with a hematopoietic disorder were trisomy 8 and inv(16) (2/11, 18%).
Conclusion. -: An immunohistochemical panel including CD43, lysozyme, myeloperoxidase
(MPO), CD68 (or CD163), CD117, CD3 and CD20 can successfully identify the vast majority of
MS variants in formalin-fixed paraffin-embedded tissue sections. The present report expands the
spectrum of our knowledge showing that de novo MS has frequent monoblastic differentiation and
frequently carries a normal karyotype.
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Background
Myeloid sarcoma (MS) is a tumor mass of myeloblasts or
immature myeloid cells occurring in an extramedullary
site or in the bone [1]. The tumor can involve any part of
the body, but commonly involved sites include subperio-
steal bone structures of the skull, paranasal sinuses, ster-
num, ribs, vertebrae, and pelvis; lymph nodes and skin are
also common sites [1]. MS may occur de novo or concur-
rently with acute myeloid leukemia (AML) or a myelopro-
liferative disorder [1]. The rate of occurrence is
approximately 1.4% to 9% of patients with AML [2,3]. MS
is frequently mistaken for non-Hodgkin lymphoma
(NHL), small round cell tumor (neuroblastoma, rhab-
domyosarcoma, Ewing sarcoma/PNET, and medulloblas-
toma), and undifferentiated carcinoma. The diagnosis is
missed in about 50% of cases when immunohistochemis-
try is not used [4]. The most common suggested diagnosis
was that of a NHL [5].
The present study was designated to evaluate the lineage
differentiation of neoplastic cells in MS by immunohisto-
chemistry, and correlate the results with clinicopathologic
findings and cytogenetic studies.
Material
Thirteen patients with a histologic diagnosis of myeloid
sarcoma were included in the present study. The initial
diagnosis was made on core biopsies (3 cases) and surgi-
cal specimens (10 cases). The specimens were fixed in
10% formaldehyde and embedded in paraffin. Five-
micron tissue sections were stained with hematoxylin-
eosin. The use of paraffin blocks for this study meets Insti-
tutional Review Board and Health Insurance Portability
and Accountability Act requirements, and has been
approved by the Institutional Review Board at the Univer-
sity of Maryland.
Immunohistochemistry
Immunohistochemical staining was performed using an
automated slide preparation system (Benchmark XT, Ven-
tana, Tuscon, AZ), a Ventana Enhanced DAB Detection Kit
(Ventana, Tucson, AZ), and commercially available predi-
luted monoclonal antibodies: CD163 (NeoMarkers),
CD4 (Biocare Medical), myeloperoxidase, lysozyme,
CD3, CD4, CD8, CD15, CD20, CD34, CD43, CD68,
CD79a, CD117, Factor VIII (FVIII), and glycophorin A (all
Ventana, Tucson, AZ).
Chromosomal Study
Chromosomal analysis was performed on tumor speci-
mens from 11 patients at diagnosis. Cells were cultured in
RPMI 1640 medium with 20% fetal bovine serum for 24
and 48 hours, respectively. Metaphase cells were analyzed
following standard G-banding method. Their karyotypes
were interpreted according to the International System for
Human Cytogenetic Nomenclature.
Results
Demographic data
The clinical findings are shown in Table 1. The study
included six male and seven female patients with an age
range of 25 to 72 years (mean, 49.3 years) and a male to
female ratio of 1:1.2. MS de novo occurred in 4/13 (31%)
cases examined.
Sites of involvement
MS occurred in a variety of extramedullary sites (Table 1).
Nine of thirteen cases with MS (69%) had a synchronous
involvement of the bone marrow by acute leukemia, mye-
loproliferative, or myelodysplastic disorder.
Histology and immunohistochemistry
The pathologic diagnoses are shown in Table 2.
Immature granulocytic sarcomas (IGS) were characterized
by the presence of numerous (> 90%) blasts with high N/
C ratio, round or oval nucleus, dispersed chromatin and
prominent nucleolus. The cytoplasm of the majority of
neoplastic cells was agranular with a varying degree of
basophilia. Eosinophilic granulation was notable in a
minority of a cell population. The neoplastic cells in IGS
showed reactivity with CD34, CD43, CD117, and lys-
ozyme. MPO was present in a variable number of blasts,
but always <10%. Focal weak reactivity of the neoplastic
cells with antibodies to CD68 and/or CD163 was also
noted. Differentiated granulocytic sarcomas (DGS)
showed maturation to more mature neutrophils (>10% of
neoplastic cells). The neoplastic cells in DGS showed
strong reactivity with CD43, MPO, CD15, lysozyme, and
Table 1: Clinical findings in patients with myeloid sarcoma
Case Age, year/sex Site Bone marrow
1 25/M Scrotum Uninvolved
2 66/M Kidney RAEB-2*
3 27/M Testis AML, M2
4 54/F Colon AML, M2
5 58/M Orbit Uninvolved
6 72/M Skin Uninvolved
7 46/F Lymph Node Uninvolved
8 62/F Gingiva Myelofibrosis
9 36/F Vagina AML, M1
10 38/M T5, T7 CML/BP**
11 51/F Gallbladder AML, M5b
12 40/F Breast AML, M1
13 38/F Breast AML, M4
*RAEB-2: Refractory anemia with excess blasts 2
**CML/BP: Chronic myelogeneous leukemia, blast phaseDiagnostic Pathology 2007, 2:42 http://www.diagnosticpathology.org/content/2/1/42
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variably expressed CD117. CD68 and CD163 were posi-
tive in <20% of neoplastic cells.
Monoblastic sarcomas (MBLS) were composed of a large
population (> 80%) of monoblasts. The neoplastic cells
were large, with abundant eosinophilic cytoplasm, round
or oval nuclei with dispersed chromatin and one or more
prominent nucleoli. Promonocytes showed more irregu-
lar, delicately convoluted nuclear features. MBLS were
strongly positive for CD43, lysozyme, CD68, CD163,
weakly for CD4, and negative for CD34. Scattered MPO
positive cells were also noted (Figs. 1, 2, 3, 4, 5, 6, 7).
In monocytic sarcoma (MCS), the majority of neoplastic
cells showed marked nuclear lobulation and stained
strongly with antibodies to CD43, lysozyme, CD68,
CD163, and variably with MPO (Figs. 8, 9, 10, 11).
Myelomonocytic sarcomas (MMS) were characterized by
proliferation of both neutrophilic and monocytic precur-
sors with above described morphologic and immunohis-
tochemical features each comprising >20% of neoplastic
cells. The cases were notable for increased numbers of
eosinophils containing large eosinophilic granules in the
cytoplasm.
The neoplastic cells in all MS examined did not react with
antibodies to FVIII, and glycophorin A. T and B lym-
phocyte lineage-specific antigens such as CD3, CD20, and
CD79a were typically absent.
All MS were morphologically and immunophenotypically
analogous to their leukemic counterparts.
Chromosomal study
The cytogenetic findings are shown in Table 3. Chromo-
somal abnormalities were observed in 6/11 (55%) cases
examined. All patients with MS occurring de novo had a
normal karyotype (4/4, 100%). The most common
genetic abnormalities were the presence of an extra chro-
mosome 8 and inv(16) (2/11, 18%) (Fig. 12).
Comments
MS is a neoplasm of immature granulocytes, monocytes,
or both involving any extramedullary site [6]. The neo-
plasm usually occurs in patients with acute myeloid leuke-
mia, myelodysplastic or myeloproliferative disorder. It
may rarely precede peripheral blood or bone marrow
involvement, presenting a diagnostic challenge. In our
study, all patients were adults with a slight female pre-
dominance. In agreement with previous reports, the neo-
plasms occurred in different locations including the orbit,
gingiva, skin, breast, vertebral bodies, GI tract, and genito-
urinary system. [6-16].
With extensive morphological and immunohistochemical
analyses, the MS were classified into five types: a) imma-
ture granulocytic sarcoma (IGS); b) differentiated granu-
locytic sarcoma (DGC); c) monoblastic sarcoma (MBLS);
d) monocytic sarcoma (MS), and myelomonocytic sar-
coma (MMS) (Table 2). These tumors were also morpho-
logically and immunophenotypically analogous to their
leukemic counterparts. In agreement with previous
reports [5], CD43 and lysozyme were the most sensitive
markers staining a large proportion of neoplastic cells in
all tumors examined (13/13, 100%). MPO and CD117
were the most sensitive of the markers for myeloid differ-
entiation while monocytic precursors consistently
strongly expressed CD68 and CD163. Differential diagno-
sis of MS includes several entities, the majority of which
can be readily distinguished using a combination of mor-
phologic and immunohistochemical evaluation. MS is
frequently mistaken for malignant B-cell or T-cell lym-
phoma, especially when it presents without leukemic
manifestation [3]. An incomplete workup may be mis-
leading because NHL and MS share morphologic similar-
ities and both express some leukocyte antigens, such as
CD43 and CD45. In our study, B-cell and T-cell lympho-
mas were excluded by negative stains for CD20, CD79a
and CD3, respectively. In addition, blastic NK cell lym-
phoma can mimic IGS, or MBLS. The neoplastic cells con-
sistently express CD43, CD4, CD56, and, unlike MS, are
negative for MPO, CD33, CD117, lysozyme, and CD68.
Burkitt lymphoma could be excluded by negative immu-
noreactivity for B-cell-associated antigens, a relatively low
proliferation rate, and lack of t(8;14) or t(2;8), and
t(8;22) translocations.
The findings are in agreement with previous observations
and suggest that an immunohistochemical panel includ-
ing CD43, MPO, CD117, CD68 (or CD163), CD3 and
CD20 can successfully identify the majority of MS in for-
malin-fixed, paraffin-embedded tissue specimens [17-22].
Table 2: Pathologic diagnosis in patients with myeloid sarcomas
Case Pathologic diagnosis
1 Monoblastic sarcoma*
2 Myelomonocytic sarcoma
3 Granulocytic sarcoma, differentiated
4 Granulocytic sarcoma, differentiated
5 Monoblastic sarcoma*
6 Monoblastic sarcoma*
7 Monoblastic sarcoma*
8 Myelomonocytic sarcoma
9 Granulocytic sarcoma, immature
10 Granulocytic sarcoma, differentiated
11 Monocytic sarcoma
12 Granulocytic sarcoma, immature
13 Myelomonocytic sarcoma
* MS de novo.Diagnostic Pathology 2007, 2:42 http://www.diagnosticpathology.org/content/2/1/42
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Monoblastic sarcoma de novo, skin Figure 1
Monoblastic sarcoma de novo, skin. (hematoxylin-eosin, × 
100).
Monoblatic sarcoma de novo, skin Figure 2
Monoblatic sarcoma de novo, skin. Multiple mitotic figures 
are seen. (hematoxylin-eosin, × 400).
Monoblastic sarcoma de novo Figure 3
Monoblastic sarcoma de novo. Neoplastic cells are positive 
for CD43. (B-SA, anti-CD43, × 400).
Monoblastic sarcoma de novo Figure 4
Monoblastic sarcoma de novo. Neoplastic cells are positive 
for CD163. (B-SA, anti-CD163, × 400).Diagnostic Pathology 2007, 2:42 http://www.diagnosticpathology.org/content/2/1/42
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Monocytic sarcoma, gallbladder Figure 8
Monocytic sarcoma, gallbladder. (hematoxylin-eosin, × 100).
Monoblastic sarcoma de novo Figure 6
Monoblastic sarcoma de novo. One single neoplastic cell is 
positive for MPO. (B-SA, anti-MPO, × 400).
Monoblastic sarcoma de novo Figure 5
Monoblastic sarcoma de novo. Neoplastic cells are negative 
for CD3. Residual T-lymphocytes are positive with CD3 anti-
body. (B-SA, anti-CD3, × 400).
Monoblastic sarcoma de novo Figure 7
Monoblastic sarcoma de novo. Neoplastic cell are negative 
for CD34. Stain for CD34 reveals endothelial cells. (B-SA, 
anti-CD34, × 400).Diagnostic Pathology 2007, 2:42 http://www.diagnosticpathology.org/content/2/1/42
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Using the antibody panel mentioned above, we reached
the correct diagnosis in all cases examined. In cases with
megakaryoblastic and/or erythroblastic differentiation,
diagnosis can be confirmed by inclusion of one or more
lineage-specific markers, such as FVIII, CD41, CD61, glyc-
ophorin A, and hemoglobin A in the diagnostic panel
[1,23].
MS has been described in association with a variety of
chromosomal abnormalities [1,24]. In particular,
t(8;21)(q22;q22) and inv(16) are regarded as recurrent
aberrations in GS [1,3,9,15] while translocations involv-
ing 11q23 have been detected in MBLS [1]. In this study,
chromosomal aberrations were detected in 55% (6/11) of
the cases. The commonest abnormalities were +8, and
inv(16) occurring in 18% (2/11) of MS. DGS (n = 1) and
MCS (n = 1) carried trisomy 8 (n = 1) while inv(16) was
observed in IGS (n = 1) and MMS (n = 1). The findings
support the recent observation of Deeb et al. [24] who
described chromosome 8 abnormalities as the most com-
mon genetic aberration in MS. In this study, all cases car-
rying chromosomal abnormalities (6/6, 100%) had
simultaneous AML, myeloproliferative disorder or MDS.
Monocytic sarcoma, gallbladder Figure 12
Monocytic sarcoma, gallbladder. Chromosomal analysis 
reveals trisomy 8 and trisomy 13. (standard G-banding)
Monocytic sarcoma, gallbladder Figure 10
Monocytic sarcoma, gallbladder. Neoplastic cells are positive 
for CD43. (B-SA, anti-CD43, × 400).
Monocytic sarcoma, gallbladder Figure 9
Monocytic sarcoma, gallbladder. Neoplastic cells have very 
dispersed chromatin and inconspicuous nucleoli. Note irreg-
ular and delicately convoluted nuclear configuration. (hema-
toxylin-eosin, × 400).
Monocytic sarcoma, gallbladder Figure 11
Monocytic sarcoma, gallbladder. Neoplastic cells are positive 
for CD68. (B-SA, anti-CD68, × 400).Diagnostic Pathology 2007, 2:42 http://www.diagnosticpathology.org/content/2/1/42
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Similar to what was reported by others [25], we found that
inv(16) was associated with myelomonocytic differentia-
tion in at least one case. Inv(16) was also identified in
another case that was classified as IGS with multiple
cytogenetic abnormalities. Furthermore, both cases
involved the breast, in contrast to earlier reports of intes-
tinal involvement by inv(16) positive MS with monocytic
differentiation. All patients with de novo MS showed a
normal karyotype (4/4, 100%), monoblastic differentia-
tion, and lack of CD34. Previous studies revealed a corre-
lation of monocytic differentiation, lack of CD34, and
normal cytogenetics with nucleophosmin gene (NPM1)
abnormalities [26]. In adults, NPM1 gene mutations have
been identified in 50% to 60% of all AML cases with a
normal karyotype [26]. Whether this newly identified
molecular marker can aid in stratification of patients is
under clinical investigation. In addition, a recent study
showed a significant correlation between extramedullary
involvement and coexpression of MCP-1/CCR2 by M4–
M5 blasts which might help to explain some aspects of the
pattern of invasion in MS with monocytic differentiation
[27].
The correct diagnosis of MS is important for adequate
therapy, which is often delayed because of a high misdiag-
nosis rate [7]. Previous studies have indicated that the bio-
logic behavior is dramatic irrespective of presentation,
age, sex, phenotype and cytogenetics [25]. Conversely to
that reported by Pileri et al. [25], other reports showed a
shorter median survival of patients with chromosome 8
abnormalities [2] and better prognosis for patients with
GS [9]. From our experience, the occurrence of GS in
patients with hematological abnormalities has a negative
impact on median survival and prognosis (unpublished
observations).
The present report expands the spectrum of our knowl-
edge showing that de novo MS has frequent monoblastic
differentiation and frequently carries a normal karyotype.
The most common genetic aberrations in MS associated
with hematopoietic disorders were trisomy 8 and inv(16).
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